Joshua S. Fleishman

1.6k total citations · 3 hit papers
39 papers, 986 citations indexed

About

Joshua S. Fleishman is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Joshua S. Fleishman has authored 39 papers receiving a total of 986 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Molecular Biology, 11 papers in Pulmonary and Respiratory Medicine and 11 papers in Cancer Research. Recurrent topics in Joshua S. Fleishman's work include Ferroptosis and cancer prognosis (8 papers), Inflammasome and immune disorders (8 papers) and interferon and immune responses (6 papers). Joshua S. Fleishman is often cited by papers focused on Ferroptosis and cancer prognosis (8 papers), Inflammasome and immune disorders (8 papers) and interferon and immune responses (6 papers). Joshua S. Fleishman collaborates with scholars based in United States, China and India. Joshua S. Fleishman's co-authors include Sunil Kumar, Yumin Wang, Vincent Mor, Hongquan Wang, Kenneth J. Branco, C. Hawes, Joan K. Morris, Carol F. Phillips, Brant E. Fries and Jichao Chen and has published in prestigious journals such as SHILAP Revista de lepidopterología, Frontiers in Immunology and Life Sciences.

In The Last Decade

Joshua S. Fleishman

37 papers receiving 964 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bile acid metabolism and signaling in health and disease: molecular mechanisms and therapeutic targets

2024 154 citations Joshua S. Fleishman, Sunil Kumar Signal Transduction and Targeted Therapy profile →
Cuproptosis: A novel therapeutic target for overcoming cancer drug resistance

2023 140 citations Yumin Wang, Yumin Wang et al. Drug Resistance Updates profile →
Targeting epigenetic and posttranslational modifications regulating ferroptosis for the treatment of diseases

2023 110 citations Yumin Wang, Jing Hu et al. Signal Transduction and Targeted Therapy profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Joshua S. Fleishman United States	14	342	191	188	165	139	39	986
Meirong Wang China	22	553 1.6×	282 1.5×	102 0.5×	345 2.1×	127 0.9×	68	1.4k
Margaret A. Gates United States	22	284 0.8×	85 0.4×	93 0.5×	188 1.1×	198 1.4×	53	1.7k
Li Luo China	20	209 0.6×	144 0.8×	64 0.3×	156 0.9×	81 0.6×	56	1.1k
RK Goyal United States	21	180 0.5×	236 1.2×	82 0.4×	64 0.4×	113 0.8×	136	1.4k
Benjamin CY Wong Hong Kong	24	156 0.5×	421 2.2×	58 0.3×	111 0.7×	102 0.7×	54	2.1k
Sophie Pilleron United Kingdom	18	141 0.4×	178 0.9×	103 0.5×	80 0.5×	159 1.1×	61	1.4k
Sebastiano Cimino Italy	30	271 0.8×	710 3.7×	56 0.3×	97 0.6×	151 1.1×	125	2.3k
Vinay Gupta United States	20	271 0.8×	64 0.3×	99 0.5×	78 0.5×	269 1.9×	55	1.2k
Jae Jeong Yang South Korea	21	173 0.5×	185 1.0×	50 0.3×	112 0.7×	198 1.4×	51	1.1k

Countries citing papers authored by Joshua S. Fleishman

Since Specialization

Citations

This map shows the geographic impact of Joshua S. Fleishman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joshua S. Fleishman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joshua S. Fleishman more than expected).

Fields of papers citing papers by Joshua S. Fleishman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joshua S. Fleishman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joshua S. Fleishman. The network helps show where Joshua S. Fleishman may publish in the future.

Co-authorship network of co-authors of Joshua S. Fleishman

This figure shows the co-authorship network connecting the top 25 collaborators of Joshua S. Fleishman. A scholar is included among the top collaborators of Joshua S. Fleishman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joshua S. Fleishman. Joshua S. Fleishman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wang, Hongquan, Joshua S. Fleishman, Shuang Wu, et al.. (2025). cGAS-STING targeting offers novel therapeutic opportunities in neurological diseases. Ageing Research Reviews. 105. 102691–102691. 12 indexed citations

Wang, Yu, X. Zhang, Weixue Wang, et al.. (2025). cGAS-STING targeting offers therapy choice in lung diseases. Biology Direct. 20(1). 20–20. 6 indexed citations

Zhang, Shiwu, Shiwu Zhang, Zhenglu Wang, et al.. (2025). The uptake of extracellular vesicles: Research progress in cancer drug resistance and beyond. Drug Resistance Updates. 79. 101209–101209. 7 indexed citations

Zhang, Junjing, Yan Wang, Yan Wang, et al.. (2025). Small Molecules Targeting Non-Coding RNAs Regulating Ferroptosis: New Opportunities in Precision Cancer Therapy. Antioxidants and Redox Signaling. 43(4-6). 345–362.

Ge, Minghua, Xuan-Yu Chen, Ping Huang, et al.. (2025). Understanding and overcoming multidrug resistance in cancer. Nature Reviews Clinical Oncology. 22(10). 760–780. 10 indexed citations

Fleishman, Joshua S., et al.. (2025). NLRP3 Inflammasome Targeting Offers a Novel Therapeutic Paradigm for Sepsis-Induced Myocardial Injury. Drug Design Development and Therapy. Volume 19. 1025–1041. 2 indexed citations

Diolaiti, Morgan E., Huadong Chen, Junhao Lu, et al.. (2025). Structure-activity relationship studies on 2-thienylidene substituted 3-oxo-2,3-dihydrobenzofuran-7-carboxamides as poly (ADP-ribose) polymerase inhibitors. Bioorganic Chemistry. 165. 108941–108941.

Fleishman, Joshua S. & Sunil Kumar. (2024). Bile acid metabolism and signaling in health and disease: molecular mechanisms and therapeutic targets. Signal Transduction and Targeted Therapy. 9(1). 97–97. 154 indexed citations breakdown →

Dewanjee, Saikat, Hiranmoy Bhattacharya, Chiranjib Bhattacharyya, et al.. (2024). Nrf2/Keap1/ARE regulation by plant secondary metabolites: a new horizon in brain tumor management. Cell Communication and Signaling. 22(1). 497–497. 6 indexed citations

10.

Xie, Yuhao, et al.. (2024). Hepatocellular carcinoma and lipid metabolism: Novel targets and therapeutic strategies. Cancer Letters. 597. 217061–217061. 19 indexed citations

11.

Wang, Yanan, Joshua S. Fleishman, Bing Hao, et al.. (2024). Research progress on gene mutations and drug resistance in leukemia. Drug Resistance Updates. 79. 101195–101195. 4 indexed citations

12.

Smith, Elizabeth R., et al.. (2024). Cancer nuclear envelope rupture and repair in taxane resistance. SHILAP Revista de lepidopterología. 4(6). 522–530. 1 indexed citations

13.

Fleishman, Joshua S., et al.. (2024). Female C57BL/6 mice exhibit protection against nonalcoholic fatty liver disease and diabesity accompanied by differential regulation of hepatic lipocalin prostaglandin D2 synthase. Molecular and Cellular Endocrinology. 595. 112404–112404. 3 indexed citations

14.

Wang, Hongquan, Joshua S. Fleishman, Sihang Cheng, et al.. (2024). Epigenetic modification of ferroptosis by non-coding RNAs in cancer drug resistance. Molecular Cancer. 23(1). 177–177. 32 indexed citations

15.

Smith, Elizabeth R., et al.. (2024). Cell death in cancer chemotherapy using taxanes. Frontiers in Pharmacology. 14. 1338633–1338633. 10 indexed citations

16.

Wang, Yumin, Joshua S. Fleishman, Yulin Li, et al.. (2024). Non‑coding RNA‑mediated epigenetic modification of ferroptosis in non‑small cell lung cancer (Review). International Journal of Oncology. 66(1). 7 indexed citations

17.

Wang, Yumin, Yumin Wang, Yongming Chen, et al.. (2023). Cuproptosis: A novel therapeutic target for overcoming cancer drug resistance. Drug Resistance Updates. 72. 101018–101018. 140 indexed citations breakdown →

18.

Wang, Yumin, Jing Hu, Shuang Wu, et al.. (2023). Targeting epigenetic and posttranslational modifications regulating ferroptosis for the treatment of diseases. Signal Transduction and Targeted Therapy. 8(1). 449–449. 110 indexed citations breakdown →

19.

Wang, Zhijian, Yuhao Xie, Jing‐Quan Wang, et al.. (2023). Tebentafusp: A novel drug for the treatment of metastatic uveal melanoma. Drugs of today. 59(3). 179–193. 4 indexed citations

20.

Fanning, Thomas R., Barbara J. Turner, Leon E. Cosler, et al.. (1995). The quality of Medicaid data for HIV/AIDS research: Examination of a statewide data base. 10(1). 39–47. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact